Diphenhydramine: Difference between revisions

Jump to navigation Jump to search
Adeel Jamil (talk | contribs)
No edit summary
Adeel Jamil (talk | contribs)
No edit summary
 
(9 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{Details0|Diphenhydramine (oral)}}
|authorTag={{AJ}}
{{Details0|Diphenhydramine (Injection)}}
|genericName=Diphenhydramine hydrochloride
{{Details0|Diphenhydramine (topical)}}
|aOrAn=a
|drugClass=Analgesic ,  Antihistamine
|indicationType=treatment
|indication=temporarily relieves symptoms of the common cold like
runny nose, sneezing, itchy watery eyes, itchy nose or throat
|adverseReactions=[[Xerostomia]], [[dizziness]], [[dyskinesia]], [[sedatation]], [[somnolence]]
dryness of nasal mucosa, [[pharyngeal dryness]], thick sputum.
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult=* Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
:* Runny nose
:* Sneezing
:* Itchy, watery eyes
:* Itchy nose or throat
 
* Temporarily relieves these symptoms of the common cold:
:* Runny nose
:* Sneezing
 
* Dosing Information
 
:* Take every 4 to 6 hours, not more than 6 doses in 24 hours
 
[[File:Diphenhydramine dosage table01.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]
|offLabelAdultGuideSupport=* Chemotherapy-induced nausea and vomiting.
* Extrapyramidal disease - Medication-induced movement disorder.
* Hyperemesis gravidarum.
* Local anesthesia
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Diphenhydramine in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Diphenhydramine in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Diphenhydramine in pediatric patients.
 
<!--Contraindications-->
|contraindications=* Diphenhydramine is contraindicated in persons with known hypersensitivity.
|warnings=* Do not use with any other product containing diphenhydramine, even one used on skin
* To make a child sleepy
* Ask a doctor before use if you have glaucoma
* Trouble urinating due to an enlarged prostate gland
* A breathing problem such as emphysema or chronic bronchitis
* Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers
 
When using this product
marked drowsiness may occur
avoid alcoholic drinks
excitability may occur, especially in children
alcohol, sedatives and tranquilizers may increase drowsiness
be careful when driving a motor vehicle or operating machinery
If pregnant or breast-feeding,
ask a health professional before use.
 
Keep out of reach of children.
In case of overdose, get medical help or contact a Poison Control Center right away.
|clinicalTrials======Digestive=====
* Xerostomia
 
=====Neurologic=====
* Sedation
* Dizziness
* Dyskinesia
* Somnolence
 
=====Respiratory=====
* Dryness of nasal mucosa
* Pharyngeal dryness
* Thick sputum
* Bronchial dryness
 
=====Miscellaneous====
* Anaphylaxis reaction
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of Diphenhydramine in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=There is limited information regarding <i>drug interactions</i> of Diphenhydramine in the drug label.
|FDAPregCat=B
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Diphenhydramine in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of Diphenhydramine during labor and delivery.
|useInNursing=There is no FDA guidance on the use of Diphenhydramine with respect to nursing mothers.
|useInPed=* Keep out of reach of children.
* In case of overdose, get medical help or contact a Poison Control Center right away.
|useInGeri=There is no FDA guidance on the use of Diphenhydramine with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of Diphenhydramine with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of Diphenhydramine with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of Diphenhydramine in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of Diphenhydramine in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of Diphenhydramine in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of Diphenhydramine in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* Intramuscular
* Intravenous
* Oral
|monitoring=There is limited information regarding <i>Monitoring</i> of Diphenhydramine in the drug label.
 
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of Diphenhydramine in the drug label.
 
<!--Overdosage-->
|overdose=There is limited information regarding <i>Chronic Overdose</i> of Diphenhydramine in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox={{Drugbox2
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460791686
| IUPAC_name = 2-(diphenylmethoxy)-''N'',''N''-dimethylethanamine
| image = Diphenhydramine 2D skeletal.png
| width = 200
| image2 = Diphenhydramine ball-and-stick animation.gif
 
<!--Clinical data-->
| tradename = Benadryl, Unisom, Sominex, ZzzQuil,
| Drugs.com = {{drugs.com|monograph|diphenhydramine-hydrochloride}}
| MedlinePlus = a682539
| pregnancy_AU = A
| pregnancy_US = B
| legal_AU = S2
| legal_status = [[Over-the-counter drug|Over-the-counter]]
| routes_of_administration = Oral, parenteral ([[Intramuscular injection|IM]] and [[Intravenous therapy|IV]]), topical, suppository
| dependency_liability = Very low
 
<!--Pharmacokinetic data-->
| bioavailability = 40–60%<ref name="pmid2866055">{{cite journal | author = Paton DM, Webster DR | title = Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines) | journal = Clin. Pharmacokinet. | volume = 10 | issue = 6 | pages = 477–97 | year = 1985 | pmid = 2866055 | doi = 10.2165/00003088-198510060-00002 }}</ref>
| protein_bound = 98–99%
| metabolism = Various [[cytochrome P450]] liver enzymes: [[CYP2D6]] (80%), [[CYP3A4|3A4]] (10%)<ref>{{cite web | author = | title = Showing Diphenhydramine (DB01075) | url = http://www.drugbank.ca/drugs/DB01075 | publisher = DrugBank | accessdate = 5 September 2009 }}</ref>
| elimination_half-life = 8 hours (children)<ref name="pmid2391399">{{cite journal | author = Simons KJ, Watson WT, Martin TJ, Chen XY, Simons FE | title = Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children | journal = J. Clin. Pharmacol. | volume = 30 | issue = 7 | pages = 665–71 |date=July 1990 | pmid = 2391399 | doi = 10.1002/j.1552-4604.1990.tb01871.x }}</ref><br />9 to 12 hours (adults)<ref name="pmid2391399" /><br />17 hours (elderly)<ref name="pmid2391399" />
| excretion = 94% through the urine, 6% through feces<ref name="pmid3962845">{{cite journal | author = Garnett WR | title = Diphenhydramine | journal = Am. Pharm. | volume = NS26 | issue = 2 | pages = 35–40 |date=February 1986 | pmid = 3962845 | doi = }}</ref>
 
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 58-73-1
| ATC_prefix = D04
| ATC_suffix = AA32
| ATC_supplemental =  {{ATC|D04|AA33}}, {{ATC|R06|AA02}}
| PubChem = 3100
| IUPHAR_ligand = 1224
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01075
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2989
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 8GTS82S83M
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D00669
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4636
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 657
 
<!--Chemical data-->
| C = 17 | H = 21 | N = 1 | O = 1
| molecular_weight = 255.355 g/mol
| smiles = O(CCN(C)C)C(c1ccccc1)c2ccccc2
| InChI = 1/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZZVUWRFHKOJYTH-UHFFFAOYSA-N
}}
|mechAction=*
 
<!--Structure-->
|structure=*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of Diphenhydramine in the drug label.
 
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of Diphenhydramine in the drug label.
 
<!--How Supplied-->
|howSupplied=*
 
<!--Patient Counseling Information-->
|storage=store at 20°-25°C
|fdaPatientInfo=* Marked drowsiness may occur
* Avoid alcoholic drinks
* Excitability may occur, especially in children
* Alcohol, sedatives and tranquilizers may increase drowsiness
* Be careful when driving a motor vehicle or operating machinery
|alcohol=* Avoid alcoholic drinks.
 
* Alcohol, sedatives and tranquilizers may increase drowsiness.
|brandNames=* Benadryl®
* Benylin Decongestant Cough®
* Diphenhist
* Diphenyl®
* Genahist®
* Geridryl®
* Nytol Quickcaps®
* Nytol Quickgels®
|lookAlike=* Benadryl®  - benazepril®
* diphenhydrAMINE®  - dimenhyDRINATE®
|drugShortage=
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage}}
{{LabelImage}}
<!--Pill Image-->
 
 
 
<!--Label Display Image-->
 
 
 
 
 
<!--Category-->
 
[[Category:Drug]]

Latest revision as of 15:52, 6 May 2015